Current application of cannabidiol (CBD) in the management and treatment of neurological disorders

Neurol Sci. 2020 Nov;41(11):3085-3098. doi: 10.1007/s10072-020-04514-2. Epub 2020 Jun 16.


Cannabidiol (CBD), which is nonintoxicating pharmacologically relevant constituents of Cannabis, demonstrates several beneficial effects. It has been found to have antioxidative, anti-inflammatory, and neuroprotective effects. As the medicinal use of CBD is gaining popularity for treatment of various disorders, the recent flare-up of largely unproven and unregulated cannabis-based preparations on medical therapeutics may have its greatest impact in the field of neurology. Currently, as lot of clinical trials are underway, CBD demonstrates remarkable potential to become a supplemental therapy in various neurological conditions. It has shown promise in the treatment of neurological disorders such as anxiety, chronic pain, trigeminal neuralgia, epilepsy, and essential tremors as well as psychiatric disorders. While recent FDA-approved prescription drugs have demonstrated safety, efficacy, and consistency enough for regulatory approval in spasticity in multiple sclerosis (MS) and in Dravet and Lennox-Gastaut Syndromes (LGS), many therapeutic challenges still remain. In the current review, the authors have shed light on the application of CBD in the management and treatment of various neurological disorders.

Keywords: Cannabidiol; Efficacy; Ethicality; Neurologic disorders.

Publication types

  • Review

MeSH terms

  • Anticonvulsants / therapeutic use
  • Cannabidiol* / therapeutic use
  • Cannabis*
  • Epilepsy* / drug therapy
  • Humans
  • Lennox Gastaut Syndrome*


  • Anticonvulsants
  • Cannabidiol